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Abstract
Background: Short interfering RNAs (siRNAs) have been shown to induce immune stimulation
through a number of different receptors in a range of cell types. In primary cells, both TLR7 and
TLR8 have been shown to recognise siRNAs however, despite the identification of a number of
TLR7/8 stimulatory RNA motifs, the complete and definitive sequence determinants of TLR7 and
TLR8 are yet to be elucidated.
Results: A total of 207 siRNA sequences were screened for TLR7/8 stimulation in human PBMCs.
There was a significant correlation between the U count of the U-rich strand and the
immunostimulatory activity of the duplex. Using siRNAs specifically designed to analyse the effect
of base substitutions and hybridisation of the two strands, we found that sequence motifs and the
thermodynamic properties of the duplexes appeared to be the major determinants of siRNA
immunogenicity and that the strength of the hybridisation interaction between the two strands
correlated negatively with immunostimulatory activity.
Conclusion: The data presented favour a model of TLR7/8 activation by siRNAs, in which the two
strands are denatured in the endosome, and single-stranded, U-rich RNA species activate TLR7/8.
These findings have relevance to the design of siRNAs, particularly for in vivo or clinical applications.
Background
The mammalian innate immune system utilises a number
of protein receptors for the identification of microbial
molecules. Amongst these are several receptors specific for
foreign ribonucleic acids (RNAs), including Toll-like
receptor 3 (TLR3), TLR7, TLR8, RIG-I, MDA5 and PKR
(reviewed in [1]). These receptors are specifically activated
by different microbial RNA features, including double-
strandedness (TLR3, RIG-I, MDA5, PKR) [2-4], extracellu-
lar or endosomal localization (TLR3, TLR7, TLR8) [5,6]
and/or the presence of 5'-triphosphates (RIG-I, PKR) [7-
9]. The engagement of these receptors by their cognate lig-
ands induces the expression of anti-viral genes, including
cytokines and type I interferons (IFNs).
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Short interfering RNAs (siRNAs) are routinely used in lab-
oratory settings, and hold promise for a range of therapeu-
tic applications [10,11]. Although initially thought to
bypass the innate immune system by virtue of their size
[12,13], siRNAs have more recently been shown to induce
immune stimulation in a variety of in vivo, and in vitro set-
tings (reviewed in [14-16]). Synthetic siRNA duplexes
have now been show to activate PKR in glioblastoma cells
[17], RIG-I in glioblastoma cells and primary human
monocytes [7,18], TLR3 in HEK293 cells and murine
models [19,20], TLR7 in murine leukocytes and human
plasmacytoid dendritic cells [21], and TLR8 in human
monocytes [22]. In addition, a number of groups have
demonstrated innate immune stimulation by siRNAs in
human peripheral blood mononuclear cells (PBMCs)
without defining the cell or receptor specificity [23-26].
Whilst the activation of RIG-I, PKR and TLR3 described
above does occur with specific types of siRNA and in spe-
cific cellular contexts, it appears that the major innate
immune response to standard 21 mer siRNAs (i.e. without
5'-triphosphates and with 3'-overhangs) is activation of
TLR7 and/or TLR8 in leukocytes [21-26]. In isolated
human leukocytes immune stimulation has been shown
to be mediated by TLR7/8 activation since it is dependent
upon endosomal maturation (excluding activation of
cytosolic receptors such as RIG-I), and mediated by single-
stranded RNA in a sequence-dependent fashion (exclud-
ing TLR3) [21,22,24,26]. Sequence-dependent activation
of TLR7 by such siRNA has been demonstrated in primary
human pDCs, murine leukocytes and in in vivo murine
models [21]. Sequence-dependent activation of human
monocytes through an endosomal pathway has also been
reported [22], presumably through activation of TLR8
which is the primary sensor of single-stranded RNA in
these cells [27]. Stimulation of human PBMCs with siRNA
can lead to production of either IFNα or TNFα or both
simultaneously, leading to the hypothesis that differences
in the sequence specificity of TLR7 and TLR8 may cause a
given immunostimulatory sequence to activate pDCs
through TLR7 and/or monocytes through TLR8 [26].
TLR7 and TLR8 are both activated by single-stranded RNA.
The precise sequence requirements for their activation
have not yet been elucidated, however, it has been dem-
onstrated that G and U rich sequences tend to stimulate
TLR7 causing IFNα production from pDCs, and A and U
rich sequences tend to stimulate TLR8 causing production
of both IFNα and TNFα from monocytes [28-30]. It has
not yet been determined whether these base preferences
also affect the activation of TLR7/8 by siRNA (it should be
noted that for an siRNA duplex of a given length, the total
G+U content is identical irrespective of the sequence and
is equal to the length of the siRNA). However, it has been
shown that TLR7/8 immunostimulatory duplex siRNAs
are less active than their component single strands, sug-
gesting that activation of TLR7/8 by siRNAs is induced by
the latter [31]. In support of this hypothesis, specific G
and U rich TLR7 stimulatory motifs (GUCCUUCAA and
UGUGU) have been identified in the single strand com-
ponents of two siRNA duplexes [21,24].
Thus, it appears that the primary mechanism of innate
immune stimulation by siRNAs is the activation of TLR7/
8 by a single strand of the siRNA duplex (which may
become denatured in the endosome, allowing release of
the immunostimulatory strand). In the present study, we
have investigated the sequence requirements for siRNA
stimulation of TLR7/8 by screening 207 siRNA sequences
for stimulation of human PBMCs. We found that
sequence motifs and the thermodynamic properties of the
duplexes appeared to be the major determinants of siRNA
immunogenicity. In addition, we have identified a
number of highly immunogenic RNA sequences.
Results and Discussion
Assay development
In order to determine the determinants of immunogenic-
ity of siRNAs, we initially sought to develop a sensitive
and relatively high-throughput assay for the detection of
innate immune stimulation by short duplex RNAs. The
logical choice of target cells for such an assay is primary
human PBMCs, which have been shown to produce pro-
inflammatory cytokines and IFN in response to siRNAs,
through activation of TLR7 and/or TLR8 [21,22,24-26].
These primary cells have the additional advantage that,
unlike TLR7 transfected immortalised cell lines, they
appear to fully recapitulate in vivo TLR signalling [30]. We
and others [32,33], had shown that the human hepatoma
cell line Huh7, harbouring an HCV replicon that expresses
a luciferase reporter, is a sensitive and easily assayed sys-
tem for detection of IFN. Therefore, we chose to employ
an assay system in which innate immunostimulation of
PBMCs by siRNAs is detected using inhibition of HCV rep-
lication as a surrogate marker for IFN production. Such
assay systems have been shown to be dependent on
immune stimulation of the leukocytes (since treatment of
Huh7 cells with a broad range of TLR agonists in the
absence of leukocytes does not inhibit replication of the
HCV replicon) and to be dependent upon secretion of
IFNα from the activated leukocytes (as shown by neutral-
izing mAb experiments) [32,33].
To determine the optimal density of PBMCs for such an
assay, non-cryopreserved primary human PBMCs at den-
sities of 5–20 × 104 cells/100 μl were treated with 50 nM
(a comparable concentration to previous studies refer-
ences 21–26) siRNAs complexed with DOTAP (which has
been shown to be the most effective complexation agent
for the detection of innate immune activity of siRNAsBMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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[26]). After 24 hours, the supernatant was transferred to
Huh7-Luc cells, which were incubated for a further 24
hours to allow inhibition of HCV replication by IFN,
before luciferase expression was assayed. A range of differ-
ent siRNAs were tested. Of these, three (siGFP19+2,
siGFP27+0 and siGFP 27+2) were variants of the same
GFP targeting siRNA, which had been shown to induce
cytokine and IFN induction in PBMCs [26] and differed
only in length and the presence or absence of 3' 2 nucle-
otide overhangs; one (siNP_1496) was an Influenza A tar-
geting siRNA which had been shown to induce off-target
immune effects [25]; three (siGC47, siCNT3, siCNT4)
were commercially obtained control siRNA without target
sites in the human transcriptome; and two (siCyan1 and
siCyan2) were designed to target a cyan fluorescent pro-
tein gene. In the absence of siRNA (both in untreated
PBMCs and PBMCs treated with DOTAP alone) there was
a cell density-dependent suppression of HCV replication
(presumably due to constitutive IFN production from the
PBMCs) with background HCV suppression of the order
of 50% at a density of 20 × 104 PBMC/100 μL (Figure 1A).
By contrast, background HCV inhibition was slight at a
density of 5 × 104 PBMCs/100 μL. At this density, HCV
inhibition was observed following treatment of the
PBMCs with almost all of the siRNAs, with 4 siRNAs
inducing 100% HCV inhibition (Figure 1A). Thus, 5 × 104
PBMCs/100 μl appeared to provide the necessary dynamic
range for assaying innate immune stimulation by siRNAs,
and this density was used for further experiments.
In order to demonstrate that the PBMC/Huh7-Luc assay
system was capable of measuring differences in immunos-
timulatory activity between different siRNAs, we assessed
the dose responses of 4 of the above mentioned siRNA: 2
strong immunostimulants (siCyan1 and siCyan2) and 2
moderate immunostimulants (siGFP19+2 and
siNP_1496). Each of these duplexes induced a dose-
dependent response from PBMC, with clear differences
between the activity of each detectable in this assay (Fig-
ure 1B–E). This response was dependent upon endosomal
maturation (and was therefore not mediated by cytosolic
RNA receptors), since pre-treatment of the PBMCs with
chloroquine inhibited IFNα production in a dose-
dependent manner.
Screening siRNA duplexes for TLR7/8 activation
Having established a working assay for TLR7/8 activation
by siRNA, we sought to identify the sequence determi-
nants of this activation. We performed a 4-point (1.56,
6.25, 25 and 100 nM) dose response curve for 207 siRNA
duplexes (21 nucleotide strands with 2 base 3' overhangs
– see Additional File 1) complexed with DOTAP. At a con-
centration of 100 nM, we observed a range of innate
immune stimulation from undetectable up to the maxi-
mum quantifiable by the assay (Figure 2A). The immu-
nostimulation observed was dependent upon endosomal
maturation, since pre-treatment of the PBMCs with chlo-
roquine abrogated replicon suppression for every siRNA
duplex tested (data not shown). Since it seemed probable
that denaturation of the strands was required for activa-
tion of TLR7/8, we compared the observed suppressive
activity with the free energy of hybridisation of the duplex.
We found a significant correlation (p < 0.0001) between
this parameter and immunostimulatory activity (Figure
2B), suggesting that denaturation of the strands was
indeed required for activation of TLR7/8.
Although apparently affected by characteristics of the
duplex (such as the free energy of hybridisation as dis-
cussed above), immune activation of PBMCs by siRNAs
generally appears to be mediated by a single U rich strand
of the siRNA [21,31]. We compared the U content of both
strands in each of the 207 duplexes, and selected the
strand with the higher U content as being the probable
immunostimulatory strand. Consistent with this model,
there was a significant correlation between the U count of
the U-rich strand and the immunostimulatory activity of
the duplex (Figure 2C). G content has also been postu-
lated to promote activation of TLR7/8 [21], however, we
saw no correlation between combined U+G content and
activity (Figure 2D).
The above analysis made the assumption that the more U
rich strand of each duplex was responsible for the major-
ity of the immunostimulatory activity observed for that
duplex. To assess the validity of this assumption, we inves-
tigated the immunostimulatory activity of the individual
strands from 4 of the most highly immunostimulatory
duplexes (RS002, RS009, siCyan2 and siRNA9.2). In each
case, the U-rich strand elicited greater IFN production
from PBMCs (Figure 3), confirming the underlying
premise of the analysis and validating the findings of pre-
vious studies that TLR 3 is not involved in the sensing of
siRNA molecules in isolated human leukocytes (since sin-
gle-stranded RNA is not a ligand for TLR3).
To identify the sequence determinants of TLR7/8 activa-
tion by siRNAs, we performed alignments of the U-rich
strands from each of the duplexes. For this analysis, we
excluded those siRNAs in which both strands had equal U
content, leaving 181 duplexes for analysis. The frequency
of each base at each position was determined for the top
and bottom quartiles of activity (45 strands each), and
this was compared to the relative frequencies of each base
in the U-rich strand of the population (Figure 4). From
this analysis, several sequence features that promoted or
impaired TLR7/8 activation were suggested. Features that
appeared to promote TLR7/8 activation were: G bases at
positions 2 and 13, A bases at positions 7, 8 and from 16–
19, an absence of C bases in positions 16–19, and anBMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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Optimization of assay for detection of innate immune stimulation of PBMCs by siRNA Figure 1
Optimization of assay for detection of innate immune stimulation of PBMCs by siRNA. Supernatant from PBMCs 
treated with DOTAP complexed siRNAs for 24 hours was applied to Huh7-Luc cells. Luciferase expression was assayed 24 
hours after treatment with supernatant. Each point represents the mean of triplicate samples. Error bars indicate standard 
deviation. (A) The indicated densities (cells/100 μL) of PBMCs were stimulated with 40 nM indicated siRNAs. (B)-(E) Dose 
response curves performed using PBMCs at a density of 50,000/100 μL in the presence or absence of chloroquine at the indi-
cated concentrations.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
Page 5 of 13
(page number not for citation purposes)
absence of G bases from positions 5–8 and 18. Features
that appeared to impair TLR7/8 activation were: C bases at
positions 4, 9, 10, 12 and 15, and G bases at positions 5,
8, 11 and 16. Most of the duplexes tested included 3' over-
hangs comprising UU or TT (deoxy base) dinucleotides.
We also found that TT overhangs were over represented in
the bottom quartile of immunostimulatory activity, sug-
gesting that UU overhangs can, in some cases, contribute
to the activation of TLR7/8. These features suggested that
the degree of TLR7/8 activation induced by a given duplex
is dependent upon stimulatory motifs in the U-rich strand
(containing some G and A nucleotides), but is impaired
by CG or GC "clamps" which inhibit the release of the
active strand from the duplex.
To more specifically investigate the effect of each of the
above-mentioned sequence features on the TLR7/8 activa-
tion activity of siRNAs, we tested the immunostimulatory
activity of a number of siRNAs specifically designed to
incorporate these features in a poly-U background. Com-
pared with a poly-U/Poly-A duplex, duplexes containing
even a single G-nucleotide at either position 2 or position
13 of the U-rich strand demonstrated strikingly increased
immunostimulation of PBMCs (Figure 5). Introduction of
A-nucleotides at positions 7 and 8, or 18 and 19 produced
more modest increases in activity. Treatment of PBMCs
with the U-rich strand alone recapitulated (and in many
cases exceeded) the immunostimulatory activity of the
duplex. By contrast, none of the corresponding A-rich
complementary strands demonstrated activation of TLR7/
8 (data not shown). Dose responses for the individual U-
rich strands containing G-nucleotides, indicated an addi-
tive effect of G-nucleotides at position 2 and 13, but inclu-
sion of A-nucleotides at positions 7, 8, 18 and 19 did not
appear to increase activity further (Figure 6). When
PBMCs were replaced in the assay by purified pDCs (thus
Innate immune stimulation of PBMCs by 207 siRNAs Figure 2
Innate immune stimulation of PBMCs by 207 siRNAs. Supernatant from PBMCs treated with 100 nM DOTAP com-
plexed siRNAs for 24 hours was applied to Huh7-Luc cells. Luciferase expression was assayed 24 hours after treatment with 
supernatant. Each point represents the mean of triplicate samples. (A) Frequency histogram of replicon inhibition by all 207 
siRNAs in 5% bins. (B) Correlation between replicon inhibition an d free energy of hybridisation (ΔG) for all 207 siRNAs. (C) 
Correlation between replicon inhibition and U content for the strand of the duplex with higher U content (or both strands for 
duplexes with equal U content in both strands). (D) Correlation between replicon inhibition and U+G content for the strand 
of the duplex with higher U+G content (or both strands for duplexes with equal U+G content in both strands).BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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making the assay specific for TLR7), G-nucleotides at posi-
tions 2 or 13 again caused substantial increases in immu-
nostimulatory activity, with position 2 appearing to
produce a stronger effect than position 13 (Figure 5). In
pDCs, however, the inclusion of A-nucleotides in the U-
rich strand had only a very modest effect on immunostim-
ulatory activity, and inclusion of A-nucleotides in a
sequence containing G-nucleotides at positions 2 and 13
actually decreased immunostimulation. These findings
suggest that A nucleotides may preferentially affect recog-
nition of short RNAs by TLR8.
Inclusion of features (CG or GC dinucleotides) predicted
to decrease the immunostimulatory activity of the duplex
generally led to increases in immunostimulation of both
PBMCs and pDCs relative to poly-U for both the U-rich
single strand and the annealed duplex (Figure 7). How-
ever, given the marked enhancement in activity observed
for Poly-U oligos containing even a single G-nucleotide
(above), it appeared likely that any impairment of TLR7/
8 stimulation conferred by increased hybridisation
strength may have been masked by the much greater stim-
ulatory activity of the U-rich strand following introduc-
tion of a CG or GC "clamp". This hypothesis was
supported by the observation that despite the individual
U-rich strands of the CG/GC containing duplexes exhibit-
ing potent immunostimulatory activity relative to Poly-U,
this activity was largely negated in several of the corre-
sponding duplexes, most notably the RNA duplex
(All_GC) which contained 4 CG/GC "clamps". This effect
was also observed in purified pDCs, in which all of the
CG/GC containing duplexes demonstrated reduced
immunostimulatory activity relative to the U-rich strand
alone (Figure 7).
The above findings suggested that CG or GC clamps inter-
spersed along the length of an siRNA duplex act to inhibit
TLR7/8 activation by increasing the strength of hybridiza-
tion between the two strands, and thus impair the release
of stimulatory single-stranded RNA. However, introduc-
tion of such clamps into the siRNA duplex complicates the
analysis by appearing to increase the stimulatory activity
of the active single stranded RNA sequence through the
introduction of G nucleotides. To specifically test the
effect of increasing the strength of the hybridisation inter-
action without changing the sequence of the stimulatory
strand, we used locked nucleic acid (LNA) chemistry. LNA
bases were incorporated into the non-stimulatory strand
of 4 highly active duplexes (RS002, RS009, siCyan2 and
siRNA9.2) at positions corresponding to 4,5,8,9,11,12,15
and 16 of the stimulatory strand (mimicking the GC
clamps tested above), and the immunostimulatory activ-
ity of these duplexes was assessed in PBMCs (Figure 8). In
each case we found that duplexes containing LNAs were
significantly less active than the corresponding fully-ribo-
nucleotide duplex. This finding was in contrast to a previ-
ous report, in which an siRNA9.2 duplex including 4 LNA
bases at both the 5' and 3' ends of non-stimulatory strand
of the duplex was no less immunostimulatory than a
fully-ribonucleotide duplex [21]. To assess whether this
discrepancy was related to differences in the assay tech-
nique, we tested such an LNA modified siRNA in our
assay. LNA modification of the 4 terminal hybridizing
bases of the non-stimulatory strand did not significantly
decrease the immunostimulatory activity of the duplex, a
result that was highly consistent with previous findings.
The reason that, in this case, LNA modification in the cen-
tre of the duplex impairs immunostimulation whereas
LNA modification at the termini does not is not clear. It is
possible that in terminally modified duplexes the centre
section may be sufficiently denatured in the endosome to
Innate immune stimulation of PBMCs by single-stranded and  annealed siRNAs Figure 3
Innate immune stimulation of PBMCs by single-
stranded and annealed siRNAs. Supernatant from 
PBMCs treated with 100 nM DOTAP complexed RNAs for 
24 hours was applied to Huh7-Luc cells. Luciferase expres-
sion was assayed 24 hours after treatment with supernatant. 
Each point represents the mean of triplicate samples.
Logo representation of consensus sequences of TLR7/8  activity Figure 4
Logo representation of consensus sequences of 
TLR7/8 activity. Alignments of U rich strands from the 
upper and lower quartiles of replicon inhibition (upper and 
lower panels respectively), and from the entire set of siRNAs 
tested (26 duplexes with equal U content in both strands 
excluded from the analysis).BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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activate TLR7/8 signalling. Alternatively, it is possible that
this specific terminally modified RNA strand forms a hair-
pin, making it unavailable for duplex formation and thus
ineffective in impairing TLR7/8 activation, however, fur-
ther studies are required to distinguish between these pos-
sibilities.
It has been proposed that siRNAs activate TLR7 in pDCs
leading to IFN production, and/or TLR8 in monocytes
leading to IFN and TNFα production [26]. To investigate
the sequence specificity of TLR7 and TLR8 activation, we
tested 43 of the siRNAs that we had shown to induce IFN
production in PBMCs for IFN production in pDCs (TLR7
mediated), and TNFα production in PBMCs (TLR8 medi-
ated). We observed a range of activities for both IFN pro-
duction from pDCs (further validating the findings of
previous studies that TLR 3 is not involved in the sensing
of siRNA molecules in isolated human leukocytes, since
pDCs do not express TLR3) and TNFα production from
PBMCs, although the TLR7 response in pDCs was satu-
rated in many cases (Figure 9A and 9B). The specificity of
these assays for TLR7 and TLR8 activation was confirmed
by the respective responses to the TLR7 selective agonist
CL087, and the TLR8 selective agonist CL075. Given that
immunostimulatory siRNAs might be expected to exhibit
a preference for stimulation of either TLR7 or TLR8 and
that the initial screen for activity (IFN production in
PBMCs) measures combined IFN production from TLR7
and TLR8 stimulation, it might be expected that TNFα
production from PBMCs and IFN production from pDCs
would exhibit negative correlation. However, no such cor-
relation was observed (Figure 9C). For both TNFα produc-
tion from PBMCs, and IFN production from pDCs,
moderate correlation was observed with overall IFN pro-
duction from PBMCs (data not shown), suggesting that
the differences in the affinity of each individual siRNA for
its receptor(s) may be masking any trend. However, nor-
malisation of both TNFα production in PBMCs and IFN
production in pDC to overall IFN production from
PBMCs failed to reveal a negative correlation between IFN
production from pDCs and TNFα production (data not
Innate immune stimulation of PBMCs and pDCs by siRNAs incorporating predicted TLR7/8 stimulatory motifs Figure 5
Innate immune stimulation of PBMCs and pDCs by siRNAs incorporating predicted TLR7/8 stimulatory 
motifs. Supernatant from PBMCs (left panel) or pDCs (right panel) treated with 100 nM DOTAP complexed siRNAs (single-
stranded U rich strands = Stimulatory; annealed duplexes = Annealed) for 24 hours was applied to Huh7-Luc cells. Luciferase 
expression was assayed 24 hours after treatment with supernatant. Data is expressed as replicon expression on a log scale to 
allow visualisation of differences between highly active RNA species. Each point represents the mean of triplicate samples.
Innate immune stimulation of PBMCs and pDCs by ssRNAs  incorporating predicted TLR7/8 stimulatory motifs Figure 6
Innate immune stimulation of PBMCs and pDCs by 
ssRNAs incorporating predicted TLR7/8 stimulatory 
motifs. Supernatant from PBMCs (left panel) or pDCs (right 
panel) treated with 100 nM DOTAP complexed single-
stranded U-rich RNAs for 24 hours was applied to Huh7-Luc 
cells. Luciferase expression was assayed 24 hours after treat-
ment with supernatant. Each point represents the mean of 
triplicate samples.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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shown). Thus, although a small number of individual siR-
NAs with strong preferences for TLR7 (2 sequences caused
more than 50% replicon suppression in pDCs, but secre-
tion of less than 500 pg/mL TNFα in PBMCs or TLR8 (8 of
43 caused less than 50% replicon suppression in pDCs,
but secretion of more than 500 pg/mL TNFα in PBMCs)
were identified, there were too few such sequences to
draw conclusions about sequence determinants of TLR7
or TLR8 preference. For the subset of 43 immunogenic
siRNAs described above, we also investigated both IL-8
and IP-10 expression by ELISA. IL-8 expression correlated
with TNFα expression (data not shown). IP-10 was
induced approximately equally by all sequences tested
(data not shown), and so did not allow any discrimina-
tion between sequences.
The studies described above were all performed using
standard format 21 mer siRNAs with 2 base 3' overhangs.
However, a number of other siRNA formats have been
described in the literature, including siRNAs of varying
lengths, "blunt"-ended siRNAs, hairpin RNAs and siRNAs
incorporating DNA nucleotides [34-38]. We tested the
immunostimulatory properties of a range of different
siRNA formats based upon 3 different sequences (see
Additional File 1). No discernable trend was detected (Fig-
ure 10), although longer sequences (including hairpins),
did appear to be generally slightly more immunostimula-
tory. However, other factor(s) than format (most likely
sequence dependent) appear to have been the major
determinants of immunogenicity, and given the small
number of sequences used (only 3 base sequences) we do
not consider these results to be conclusive.
Conclusion
In the present study we have used a broad-based screening
strategy to identify sequence determinants of TLR7/8 acti-
vation by standard format duplex siRNA molecules. We
found that sequence motifs contained in a single, U-rich
strand of the siRNA duplex were a major determinant of
activity, as demonstrated by the profound increase in
immunostimulation caused by the introduction of even a
single G-nucleotide into a poly-U sequence. We also
found that the thermodynamic properties of the duplex
affected TLR7/8 activation, and that the strength of the
hybridisation interaction between the two strands corre-
lated negatively with immunostimulatory activity. Thus,
our findings suggest a model of TLR7/8 activation by siR-
NAs, in which the two strands are denatured in the endo-
some, and single-stranded, U-rich RNA species activate
TLR7/8. In the course of these studies, we have also iden-
tified several RNA species that stimulate TLR7/8 more
strongly than any previously identified agent that we are
aware of. These findings have relevance to the design of
siRNAs (particularly for in vivo or clinical applications)
and to the understanding of the physiological mecha-
nisms of TLR7/8 activation. The highly immunostimula-
tory RNA species that we have identified may also be
useful in the development of pharmacological agents with
anti-viral or vaccine adjuvant applications.
Methods
Cell culture
Human hepatoma cells (Huh7) containing a stable pFK-
I389/NS3-3'/5.1 based, Luciferase expressing HCV repli-
con (Huh7-Luc) [39] were maintained in Dulbecco's
Innate immune stimulation of PBMCs and pDCs by siRNAs incorporating predicted TLR7/8 inhibitory motifs Figure 7
Innate immune stimulation of PBMCs and pDCs by siRNAs incorporating predicted TLR7/8 inhibitory motifs. 
Supernatant from PBMCs (left panel) or pDCs (right panel) treated with 100 nM DOTAP complexed siRNAs (single-stranded 
U rich strands = Stimulatory; annealed duplexes = Annealed)for 24 hours was applied to Huh7-Luc cells. Luciferase expression 
was assayed 24 hours after treatment with supernatant. Data is expressed as replicon expression on a log scale to allow visual-
isation of differences between highly active RNA species. Each point represents the mean of triplicate samples.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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modified Eagle's medium (DMEM, Invitrogen, Carlsbad
CA) containing 10% fetal calf serum (FCS, Sigma-Aldrich,
St. Louis, MO) and 750 μg/mL G418 (Invitrogen) at 37°C
in a 5% CO2 incubator.
PBMC isolation
Buffy coats were obtained from the Australian Red Cross
Blood Service. Buffy coat (50 mL) was diluted 1:3 with
DM-L wash buffer (PBS + 2% FCS). This mixture was split
into 6 separate 25 mL aliquots and each 25 mL of diluted
cells layered over 15 mL of RosetteSep DM-L (Stemcell
Technologies, Vancouver, Canada) solution. Following
centrifugation for 20 min at 1200 g, erythrocytes were dis-
carded and the mononuclear band washed with 40 mL
DM-L wash buffer. Cells were pooled in 10 mL DM-L
wash buffer prior to addition of 25 mL Ammonium Chlo-
ride solution (Stem Cell Technologies). Following 5 min
incubation on ice the cells were centrifuged at 300 g for 5
min and resuspended in 50 mL DM-L wash buffer.
Plasmacytoid dendritic cell purification
Plasmacytoid dendritic cells (pDCs) were purified by neg-
ative selection using a plasmacytoid dendritic cell isola-
tion kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer's instructions. Briefly, fresh
PBMCs were resuspended in MACS buffer (PBS pH 7.2,
0.5% BSA, 2 mM EDTA) and 100 μL PDC biotin antibody
cocktail added per 108 cells. Following incubation on ice
for 10 min the cells were washed twice with 10 mL MACS
buffer per 108 cells. Cells were incubated with 100 μL anti-
Innate immune stimulation of PBMCs by LNA modified siRNAs Figure 8
Innate immune stimulation of PBMCs by LNA modified siRNAs. Supernatant from PBMCs treated with 100 nM 
DOTAP complexed siRNAs for 24 hours was applied to Huh7-Luc cells. Luciferase expression was assayed 24 hours after 
treatment with supernatant. LNA (red) indicates that the non-stimulatory strand contained LNA modifications at positions 
hybridizing to 4, 5, 8, 9, 11, 12, 15 and 16 of the stimulatory strand. LNA-5'3' (blue) indicates that the non-stimulatory strand 
contained LNA modifications at positions hybridizing to 1–4, and 16–19 of the stimulatory strand. Each point represents the 
mean of triplicate samples. Error bars indicate standard deviation.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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Innate immune stimulation of pDCs and TNFα production by PBMCs in response to duplex siRNAs Figure 9
Innate immune stimulation of pDCs and TNFα production by PBMCs in response to duplex siRNAs. (A) Super-
natant from pDCs treated with 100 nM DOTAP complexed siRNAs for 24 hours was applied to Huh7-Luc cells. Luciferase 
expression was assayed 24 hours after treatment with supernatant. (B) Supernatant from PBMCs treated with 100 nM DOTAP 
complexed siRNAs for 24 hours was assayed for TNFα by ELISA. (C) Correlation between data in (A) and (B). Each point rep-
resents the mean of triplicate samples. Error bars indicate standard deviation.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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biotin microbeads for 15 min on ice and washed in MACS
buffer prior to being loaded on an LS column (Miltenyi
Biotec). The unlabelled fraction containing the enriched
pDC fraction was collected and cells stained with CD303-
FITC (Miltenyi Biotec) and CD45-PerCP (Becton Dickin-
son, Mountain View, CA). Analysis of pDC purity was per-
formed by flow cytometry using a FACSCalibur flow
cytometer (Becton Dickinson).
Stimulation of TLR signalling in immune cells
The following small molecule TLR ligands were dissolved
in DMSO and stored at -20°C until use: Resiquimod
(Alexis Biochemicals, Lausen, Switzerland); CL075 and
CL087 (both from Invivogen, San Diego, CA). Chloro-
quine (Sigma-Aldrich, St Louis, MO) and all siRNAs (see
Additional File 1) were resuspended in nuclease-free
water and stored at -20°C until required. Unless otherwise
indicated IFNα-2b (R&D Systems, Minneapolis, MN) was
used at a concentration of 100 U/mL. Where indicated
PBMCs were treated with up to 10 μM chloroquine and
incubated at 37°C in a 5% CO2 incubator for 1 h prior to
addition of siRNA.
Duplex siRNAs for testing were sourced from 3 different
research groups within Johnson & Johnson Research Pty
Ltd, and had been designed to a number of targets from
different species. RNA oligos and duplex siRNAs were pur-
chased from Sigma-Aldrich).
PBMCs or pDCs (84.5% CD303+, data not shown) were
stimulated with either siRNA or known TLR agonists for
24 h prior to supernatant transfer to Huh7-Luc cells, fol-
lowing previously determined experimental protocols
[32,33]. Unless otherwise indicated 50,000 PBMCs plated
in 96-well plates in 80 μL antibiotic-free 10%FCS-RPMI
were stimulated with TLR agonist (final volume of 100
μL/well; maximum 1% DMSO per well) or transfected
with siRNA complexed with DOTAP (Roche) (final vol-
ume of 100 μL/well; maximum 100 nM siRNA per well).
For complexations 10 pmol siRNA was complexed with
0.7 μg DOTAP in 10%FCS-RPMI. The mock transfection
control used the highest concentration of DOTAP (0.7 μL
DOTAP per well). After addition of stimuli the plates were
incubated at 37°C in a 5% CO2 incubator for 24 h.
For measurement of IFN production, Huh7-Luc cells were
seeded at 7500 cells/well in 80 μL antibiotic-free media
(10%FCS-DMEM) in white 96-well plates (Greiner Bio-
one, Frickenhausen, Germany). Media was removed 24 h
post-seeding and 100 μL PBMCs pre-treated for 24 h with
TLR agonist or siRNA was added to each well. After addi-
tion of PBMC supernatant the plates were incubated at
37°C in a 5% CO2 incubator for 24 h. PBMCs were subse-
quently removed and proliferation of Huh7 or Huh7-Luc
cells determined using the Cell Titre Blue (CTB) assay
(Promega, Madison, WI). Following measurement of flu-
orescence (Fluostar Optima plate reader, BMG Labtech,
Offenburg, Germany) the CTB reagent was removed and
cells lysed with 30 μL 1× Passive Lysis Buffer (Promega) at
room temperature for 10 min. Luminescence was meas-
ured every 0.5 s for 5 s using automatic substrate injection
(Luciferase assay system, Promega) and average lumines-
cence calculated for each well. TNF-α production was
measured by Quantikine ELISA (R&D systems) according
to the manufacturer's instructions.
Bioinformatics and statistical analysis
Statistical analysis was performed using Prism (GraphPad
Software, San Diego, CA) and Pipeline Pilot (Accelrys
Software, San Diego, CA) software. Logos were generated
using Phylo-mLogo 2.3 software [40]. Unless otherwise
indicated treatments were performed in triplicate and
error bars represent standard deviation.
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Immunostimulation of PBMCs by different siRNA formats Figure 10
Immunostimulation of PBMCs by different siRNA 
formats. Supernatant from PBMCs treated with 100 nM 
DOTAP complexed siRNAs (siRNA = standard 19 bp duplex 
with 2 base 3' overhangs; 19 mer blunt = 19 bp duplex with 
no overhangs, 21 P/19 G indicates 21 bp passenger strand 
annealed to a 19 bp guide strand; 19 P/17 G indicates 19 bp 
passenger strand annealed to a 17 bp guide strand; Dicer = 
dicer substrate siRNA; 25 mer blunt = 25 bp duplex with no 
overhangs; 29 mer hairpin = 29 bp hairpin RNA; 29 mer hair-
pin +3'OH = 29 bp hairpin RNA with 3'-hydroxyl group) for 
24 hours was applied to Huh7-Luc cells. Luciferase expres-
sion was assayed 24 hours after treatment with supernatant. 
Each bar represents the mean of triplicate samples. Error 
bars indicate standard deviation.BMC Immunology 2009, 10:40 http://www.biomedcentral.com/1471-2172/10/40
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